Distinguished in Fibrolamellar Carcinoma

Juliane S. Walz

Otfried Müller Str. 10, 
Tuebingen, BW, DE 
Distinguished in Fibrolamellar Carcinoma
Otfried Müller Str. 10, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Juliane Walz practices in Tuebingen, Germany. Ms. Walz is rated as a Distinguished expert by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Fibrolamellar Carcinoma, Leukemia, Severe Acute Respiratory Syndrome (SARS), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 112 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Fibrolamellar Carcinoma.

Gender
Female

Locations

Otfried Müller Str. 10, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3

112 Total Publications

HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry.
HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry.
Journal: Journal for immunotherapy of cancer
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Walz's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile